A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- GlaxoSmithKline
- Study ID
- NCT07201051
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Bronchiectasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- GSK3862995B — DRUGParticipants will be administered with dose level 1 of GSK3862995B.
- Placebo — DRUGParticipants will be administered with matching placebo.
Study Details
This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.
Key Dates
- Start date
- Oct 30, 2025
- Status verified
- Jun 2026
- Primary completion
- May 4, 2027
- Completion
- Dec 10, 2027
Study Design
- Enrollment
- 446 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: GSK3862995B Dose Level 1Participants will receive GSK3862995B Dose level 1.
- Experimental: GSK3862995B Dose Level 2Participants will receive GSK3862995B Dose level 2.
- Placebo Comparator: PlaceboParticipants will receive matching placebo.
Primary Outcome Measure
Annualized rate of Exacerbations for GSK3862995B Dose Level 1 Following Repeat Doses Compared with Placebo [ Time Frame: Up to Week 48 ]
Central Contacts
- US GSK Clinical Trials Call Center877-379-3718
- EU GSK Clinical Trials Call Center+44 (0) 20 89904466
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36608 | Lawrence Sindel (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | La Palma | California | 90623 | Andrew Morado (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Miami | Florida | 33126 | Maria Campos-Yatzkan (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Miami | Florida | 33176 | Juvenal Martinez (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Naples | Florida | 34102 | Lisette Delgado Sanchez (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Plantation | Florida | 33324 | Frank Hull (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | St. Petersburg | Florida | 33707 | Mohamed Ali Eltoum (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Rockville | Maryland | 20854 | Asefa Mekonnen (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | DuBois | Pennsylvania | 15801 | Sandeep Bansal (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Anderson | South Carolina | 29621 | Charles Thompson (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Rock Hill | South Carolina | 29732 | Michael Denenberg (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | Farhan Siddiqui (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Conroe | Texas | 77384 | Ather Siddiqi (PRINCIPAL_INVESTIGATOR) |
| GSK Investigational Site | Sugar Land | Texas | 77479 | Subodh Bhuchar (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Mobile, AL
Related Studies
- Natural History of BronchiectasisRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Acoustic Waveform Respiratory EvaluationRecruiting · Indiana University · Indianapolis, Indiana
- The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPHASE3 · Recruiting · Boehringer Ingelheim · Birmingham, Alabama
- OLE Therapy With BE Patients in Home Care StudyRecruiting · Delve Health · New Haven, Connecticut